Phaseline

Targets › SLC22A5

SLC22A5 (Organic cation/carnitine transporter 2): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 2 Phase 2, 1 Phase 4; Cardiovascular, Metabolic and endocrine, Gastroenterology; next expected readout Dec 2026.

Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. (UniProt, O76082)

Open in Phaseline: the race on SLC22A5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Beni-Suef UniversityL-Carnitine
Carnitine palmitoyltransferase substrate; facilitates fatty acid β-oxidation and energy me
SLC22A5Phase 4HepaticDec 2026
Ain Shams UniversityL-Carnitine
Carnitine supplement - enhances fatty acid oxidation and cellular energy metabolism; promo
SLC22A5Phase 2Reperfusion Injury, Myocardial; Diabetic Foot UlcerDec 2026

Conditions

Reperfusion Injury, Myocardial (1) Diabetic Foot Ulcer (1) Hepatic (1)

Modalities

mixed (1), small molecule (1)

Companies

Ain Shams University (1) Beni-Suef University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.